Egfr

Edit

Amivantamab Lazertinib Forecast to Lead US EGFR NSCLC Therapy Revenue by 2036 as Post-TAGRISSO Competition Intensifies

Nasdaq Globe Newswire 14 Jul 2026

Across the US, EU4, UK and Japan, opportunities center on post-osimertinib ...

Edit

AstraZeneca enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical (Form 6-K) (AstraZeneca plc)

Public Technologies 14 Jul 2026

AstraZeneca licenses novel EGFR inhibitor ... AstraZeneca enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical ... EGFR Mutation Testing in Lung Cancer.

Edit

AstraZeneca enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical (AstraZeneca plc)

Public Technologies 14 Jul 2026

) Complements AstraZeneca's leading portfolio of medicines targeting EGFR mutations ... About 10-15% of NSCLC patients in the US and Europe, and 30-40% of patients in Asia, have EGFR-mutated (EGFRm) NSCLC ... EGFR Mutation Testing in Lung Cancer.

Edit

Otsuka Reports Positive Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Prevented Progression to ...

The Joplin Globe 02 Jul 2026

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Jul 1, 2026-- ... .

Edit

Otsuka Reports Positive Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT� (sibeprenlimab-szsi) Prevented Progression to ...

Business Wire 02 Jul 2026

... by annualized slope and mean change from baseline in estimated glomerular filtration rate (eGFR).

Edit

EGFR+NSCLC Pipeline Expands as 25+ Companies Driving Innovation in the Therapeutics | DelveInsight

GetNews 30 Jun 2026

Inactive Products EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Key Companies EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Key Products EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)- Unmet Needs ...

Edit

EGFR-NSCLC Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 – DelveInsight | Dizal ...

GetNews 30 Jun 2026

has received clinical trial authorization in Spain to expand its Phase IIa study evaluating HT-001, a topical therapy developed to manage skin toxicities associated with epidermal growth factor receptor (EGFR) inhibitors.

Edit

Racura Oncology Doses First Patient in Phase 1 HARNESS-1 Trial of RC220 in EGFR-Mutant Non-Small Cell Lung Cancer

PR Newswire 25 Jun 2026

Racura Oncology has dosed the first patient in the HARNESS-1 Phase 1a/b trial of RC220 in combination with osimertinib for EGFR-mutant non-small cell lung cancer ... Although EGFR TKIs have transformed ...

Edit

Translational Research Results of Sacituzumab Tirumotecan (sac-TMT) in Combination with Osimertinib as First-Line Treatment for EGFR-Mutant NSCLC Published in Cancer Cell

PR Newswire 22 Jun 2026

— The study shows that EGFR-TKIs induce TROP2 upregulation in DTP cells, providing a mechanistic basis for combining sac-TMT with EGFR-TKI ... In addition, the Company is advancing clinical exploration of sac-TMT for earlier-stage EGFR-mutant NSCLC.

Edit

EGFR Non Small Cell Lung Cancer Pipeline 2026: FDA Approvals and Clinical Trials Landscape with ...

GetNews 19 Jun 2026

The EGFR Non Small Cell Lung Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase ... EGFR Non Small Cell Lung Cancer Overview.

Edit

ESMO TAT ASIA 2026 | HANSOH PHARMA PRESENTED PHASE I DATA OF HS-20117, AN EGFR/C-MET BISPECIFIC ANTIBODY, IN PATIENTS WITH EGFR EXON 20 INSERTION-MUTATED ADVANCED NSCLC (Hansoh Pharmaceutical Group Co Ltd)

Public Technologies 18 Jun 2026

HANSOH PHARMA PRESENTED PHASE I DATA OF HS-20117, AN EGFR/C-MET BISPECIFIC ANTIBODY, IN PATIENTS WITH EGFR EXON 20 INSERTION-MUTATED ADVANCED NSCLC ... HS-20117 is a fully human immunoglobulin IgG1-like bispecific antibody targeting EGFR and c-MET ... EGFR.

Edit

EGFR Inhibitors Market to Witness Upsurge in Growth at a CAGR of 7.9% During the Forecast Period (2026-2036) Owing to the Entry of Next-generation TKIs, ADCs, and Combination Strategies with Immunotherapy| DelveInsight

PR Newswire 15 Jun 2026

Scope of the EGFR Inhibitors Market Report EGFR Inhibitors Patient Population Forecast EGFR Inhibitors Therapeutics Market Size EGFR Inhibitors Pipeline Analysis EGFR Inhibitors Market Size and Trends ...

Edit

National Kidney Foundation and U.S. Pharmacy Organizations Call for Transition to Race-Agnostic eGFR in Medication Decision-Making

PR Newswire 08 Jun 2026

The recommendation calls for replacing the long-standing Cockcroft-Gault estimated creatinine clearance (eCrCL) equation with newer, race-free eGFR equations, using the 2021 CKD-EPI formula.

Edit

Otsuka Presents Positive Interim Phase 3 VISIONARY eGFR Data Showing VOYXACT® (sibeprenlimab-szsi) Preserved Kidney Function ...

Times Argus 05 Jun 2026

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Jun 4, 2026-- ....

Edit

Phase III FIND‑CKD Results Show Bayer’s KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of ...

Caledonian Record 05 Jun 2026

WHIPPANY, N.J.--(BUSINESS WIRE)--Jun 5, 2026-- ....

Podcasts:

Latest News for: egfr

Amivantamab Lazertinib Forecast to Lead US EGFR NSCLC Therapy Revenue by 2036 as Post-TAGRISSO Competition Intensifies

AstraZeneca enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical (Form 6-K) (AstraZeneca plc)

AstraZeneca enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical (AstraZeneca plc)

Otsuka Reports Positive Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Prevented Progression to ...

Otsuka Reports Positive Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT� (sibeprenlimab-szsi) Prevented Progression to ...

EGFR+NSCLC Pipeline Expands as 25+ Companies Driving Innovation in the Therapeutics | DelveInsight

EGFR-NSCLC Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 – DelveInsight | Dizal ...

Racura Oncology Doses First Patient in Phase 1 HARNESS-1 Trial of RC220 in EGFR-Mutant Non-Small Cell Lung Cancer

Translational Research Results of Sacituzumab Tirumotecan (sac-TMT) in Combination with Osimertinib as First-Line Treatment for EGFR-Mutant NSCLC Published in Cancer Cell

EGFR Non Small Cell Lung Cancer Pipeline 2026: FDA Approvals and Clinical Trials Landscape with ...

ESMO TAT ASIA 2026 | HANSOH PHARMA PRESENTED PHASE I DATA OF HS-20117, AN EGFR/C-MET BISPECIFIC ANTIBODY, IN PATIENTS WITH EGFR EXON 20 INSERTION-MUTATED ADVANCED NSCLC (Hansoh Pharmaceutical Group Co Ltd)

EGFR Inhibitors Market to Witness Upsurge in Growth at a CAGR of 7.9% During the Forecast Period (2026-2036) Owing to the Entry of Next-generation TKIs, ADCs, and Combination Strategies with Immunotherapy| DelveInsight

National Kidney Foundation and U.S. Pharmacy Organizations Call for Transition to Race-Agnostic eGFR in Medication Decision-Making

Otsuka Presents Positive Interim Phase 3 VISIONARY eGFR Data Showing VOYXACT® (sibeprenlimab-szsi) Preserved Kidney Function ...

Phase III FIND‑CKD Results Show Bayer’s KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of ...

Article Search

EXPLORE WN.com